Cridanimod - Pharmsynthez/Xenetic Biosciences

Drug Profile

Cridanimod - Pharmsynthez/Xenetic Biosciences

Alternative Names: Sodium cridanimod; Virexxa; XBIO-101

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmsynthez
  • Developer AS Kevelt; Pharmsynthez; Xenetic Biosciences
  • Class Acetic acids; Acridines; Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Interferon stimulants; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Endometrial cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer
  • Preclinical Breast cancer

Most Recent Events

  • 14 Jun 2017 Xenetic Biosciences initiates enrolment in a phase II trial for Endometrial Cancer (Combination therapy; Second line therapy or greater) in USA (NCT03077698)
  • 03 Apr 2017 Xenetic Biosciences files an IND application with the US FDA for Breast cancer
  • 15 Nov 2016 Xenetic Biosciences announces intention to submit IND application to US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top